A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: A Pediatric Oncology Group Study (Now the Children's Oncology Group)

Pediatric Blood and Cancer

Volumn 43, Issue 2, 2004, Pages 105-109

  Bell, Beverly A ^a   Brockway, G N ^a   Shuster, J J ^b   Erdmann, G ^c   Sterikoff, S ^a   Bostrom, B ^d   Camitta, B M ^e  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c PRACS Institute Ltd   (United States)

^d PRACS Institute Ltd ^*  (United States)

^e Midwest children'S' Cancer Center   (United States)

Author keywords

ALL; Childhood; Dose; Thiopurine metabolites

Indexed keywords

MERCAPTOPURINE; MERCAPTOPURINE RIBOSIDE; METHOTREXATE; NUCLEOTIDE; XANTHINE OXIDASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICAN AMERICAN; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; DRUG METABOLISM; ERYTHROCYTE METABOLISM; FEMALE; FIRST PASS EFFECT; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISPANIC; HUMAN; IN VITRO STUDY; LEUKOCYTE COUNT; LINEAR REGRESSION ANALYSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHYLATION; OPEN STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS;

EID: 3042793886     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20089     Document Type: Article

References (36)

1. Kaspers GJL. Pediatric leukemia in the new millennium. Expert Rev Anticancer Ther 2001;1:1-2.
2. Giverhaug T, Loennechena T, Aarbakkeb J. The interaction of 6-mercaptopurine and methotrexate. General Pharmacology 1999;33:341-346.
3. McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-572.
4. Dervieux T, Brenner TL, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate, in vivo. Blood 2002;2:495.
5. Bostrom B, Erdmann G. Cellular Pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993;15:80-86.
6. Balis FM, Holcenberg JS, Poplack DG, et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children's Cancer Group and Pediatric Oncology Branch study. Blood 1998;92:3569-3577.
7. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983;308:1005-1009.
8. Balis FM, Holcenberg JS, Zimm S, et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987;41:384-387.
9. Bokkerink JP, Stet EH, DeAbreu RA, et al. 6-mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 1993;45:1455-1463.
10. Bokkerink JP, Bakker MA, Hulscher TW, et al. Purine de novo synthesis as the basis of synergism of methotrexate and 6 mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 1988;37:2321-2327.
11. Presta M, Rusnati M, Belleri M, et al. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res 1999;59:2417-2424.
12. Dervieux T, Blanco JG, Krynetski EY, et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 2001;61:5810-5816.
13. Rostami-Hodjegan A, Lennard L, Lilleyman JS. The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol 1995;40:217-222.
14. Innocenti F, Danesi R, Favre C, et al. Variable correlation between 6-mercaptopurine metabolites in erythrocytes and hematologic toxicity: Implications for drug monitoring in children with acute lymphoblastic leukemia. Ther Drug Monit 2000;22:375-382.
15. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-1823.
16. Erdmann GR, France LA, Bostrom B, et al. A reversed-phase HPLC approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990;4:47-51.
17. Harms DO, Erb N, van de Loo R, et al. Monitoring of maintenance treatment of acute leukemia by regular measurement of mercaptopurine metabolites in capillary blood. Blood 2000;96:721a.
18. Relling MV, Hancock ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999;93:2817-2823.
19. Hale JP, Lilleyman JS. Importance of 6-mercaptopurine dose in lymphoblastic leukemia. Arch Dis Child 1991;66:462-466.
20. Tolar J, Bostrom BC, Lee M, et al. Oral 6-mercaptopurine protects against fatal relapses in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group study CCG 1922. J Pediatr Hematol Oncol 2000;22:378.
21. Chrzanowska M, Koleckib P, Duczmal-Cichockab B, et al. Metabolites of mercaptopurine in red blood cells: A relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci 1999;8:329-334.
22. Lennard L, Keen D, Lilleyman JS. Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 1986;40:287-292.
23. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 1994;343:1188-1190.
24. Arndt CA, Balis FM, McCully CL, et al. Bioavailability of low-dose vs. high-dose 6-mercaptopurine. Clin Pharmacol Ther 1988;43:588-591.
25. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy: A Pediatric Oncology Group study. J Clin Oncol 1998;16:1712-1722.
26. GlaxoSmithKline (March 2002). Purinethol: Prescribing information. June 3, 2002. http://www.gsk.com
27. DeLemos M, editor. 1994. Cancer drug manual: BC Cancer Agency.
28. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukemia: A possible indicator of non-compliance? Br J Cancer 1995;72:1004-1006.
29. Lilleyman JS, Lennard L. Non-compliance with oral chemotherapy in childhood leukaemia: An overlooked and costly cause of late relapse. Br J Med 1996;313:1219-1220.
30. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: Nature and extent of individual variation. Clin Pharmacol Ther 1991;6:663-672.
31. Lilleyman JS, Lennard L, Rees CA, et al. Childhood lymphoblastic leukemia: Sex differences in 6-mercaptopurine utilization. Br J Cancer 1984;49:703-707.
32. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487-491.
33. Kham SK, Tan PL, Tay AH, et al. Thiopurine methyltransferase polymorphisms in a multiracial Asian population and children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2002;24:353-359.
34. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 2001;11:275-278.
35. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999;8:371-376.
36. Zimm S, Reaman G, Murphy RF, et al. Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia. Cancer Res 1986;46:1495-1498.